#Duchenne muscular dystrophy is a rare muscle disorder affecting approx. 1 in 3,500–5,000 male births worldwide, mostly diagnosed between the ages of 2-6. On Feb 28, #Santhera will recognize #RareDiseaseDay to raise awareness of those living with #DMD and other rare diseases.

#santhera #theirfutureourfocus #Duchenne #DMD #RareDiseaseDay

Proud to be a partner of @mdaorg’s 2023 MDA Clinical & Scientific Conference in Dallas, March 19-22. The conference will explore the latest research advancements & clinical achievements in #neuromuscular disease. Learn more: mdaconference.org #MDAconference #MDA #Santhera

#Santhera #Duchenne #DMD #MuscularDystrophy #MDAconference #MDA #Neuromuscular #ClinicalCare #Research Muscular Dystrophy Association

Congratulations World Health Organization (WHO) on your 75th anniversary. HEALTH FOR ALL All envisions that all people have good health for a fulfilling life in a peaceful, prosperous, and sustainable world. #HealthForAll #WHO75 #santhera #theirfutureourfocus #Duchenne #DMD

Next week, #CureDuchenne will bring patients, caregivers & HCPs together for the CureDuchenne Futures Conference. We are proud to have Rob Halter, Field Medical Director, speaking as part of a panel on preserving muscle during Friday’s (April 21) agenda. #santhera #Duchenne #DMD

Excited to be at the #CureDuchenne Futures Conference in San Diego/CA which is focused on bringing education, connection, and hope to the #Duchenne community. Visit our booth to learn about our mission to improve the lives of those living with #DMD. #Santhera #theirfutureourfocus

Vamorolone NDA mid-cycle review meeting by FDA completed! “We'll work closely with FDA during the remainder of the review process and are confident about being able to provide an emerging therapy soon,” said Shabir Hasham, MD, #Santhera's CMO. bit.ly/40B6RT0 #duchenne

#Santhera just announced its preliminary unaudited 2022 financial results , reported on progress with its lead DMD drug candidate, and provided updates on its strategic and financing initiatives. Visit our press release & conference call replay here bit.ly/3hWJH65.

#Santhera is excited to be attending the #PPMD Annual Conference Jun 29-Jul 1 in Dallas, TX! Join us for the “Potential Upcoming Approvals” presentation on Friday, June 30, where Tom White, Field Medical Director, Santhera will be one of the featured presenters. #Duchenne #DMD

Today, #Santhera announced its half-year 2023 results and provided updates on its business and financing initiatives. Progress made will also be shared in a conference call today at 14:30 CEST / 08:30 EST. Join us! For dial-in details and PR: bit.ly/44J2GXg.

We're at the H.C. Wainwright & Co, LLC 25th Annual Global Investment Conference in NYC! Our CEO Dario Eklund will share updates and future goals of #Santhera. Join him on Sep 12, 2023, at 10:00 AM EDT, room Kennedy II, Lotte NY Palace Hotel. #HCWainright #investorconference #DMD

We are participating in the 2023 WMS World Muscle Society conference! Our medical representatives are looking forward to meeting health care professionals at our scientific exhibit (booth #19). #Santhera #theirfutureourfocus #Duchenne #musculardystrophy #DMD #WMS2023

#Santhera and Catalyst are proud to partner in the development of an innovative therapy to address unmet needs in the #Duchenne muscular dystrophy community! Our med reps are welcoming HCPs at #WMS2023 booth #19. #theirfutureourfocus #musculardystrophy #DMD

We are thrilled to announce that the U.S. FDA has approved our novel corticosteroid drug for the treatment of #Duchenne muscular dystrophy (#DMD) in children and adults aged 2 years and older. Read more here bit.ly/3Qf1tBz. #Santhera #theirfutureourfocus

#santhera #theirfutureourfocus #Duchenne #DMD #PPMDeveryfuture #BeckerMuscularDystrophy #rarediseaseday #raredisease

With rare disease day coming up on February 29, Dr. Kerry Nip, our Head Medical Affairs EU & ROW, shares what it means to her in her role at Santhera. #Santhera #theirfutureourfocus #Duchenne #DMD #rarediseaseday #raredisease #showyourcolours

At #Santhera, we are dedicated to developing medicines to meet the needs of patients living with #raredisease. Please join us in recognizing #RareDiseaseDay on February 29, 2024, when we come together to raise awareness for rare disease! #theirfutureourfocus #Duchenne #DMD

At #Santhera, we recognize the vital significance of #InternationalWomensDay in celebrating the achievements and contributions of women worldwide. Together, let's continue to champion for opportunities for women in our organization and beyond. #IWD2024 #EmpowerWomen #WomenLeaders

Sperogenix Therapeutics, #Santhera's specialized rare disease partner for China, announced: 曙方医药杜氏肌营养不良新药Vamorolone上市许可申请获受理! China's NMPA has accepted for priority review the NDA for this new medicine to treat #DMD. More at bit.ly/43AxVoo #Duchenne